Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bisphosphonates in the treatment of HIV-related osteoporosis.

Literature DB >> 25424437

Bisphosphonates in the treatment of HIV-related osteoporosis.

Fabio Vescini¹, Franco Grimaldi.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2014 PMID： 25424437 DOI： 10.1007/s12020-014-0488-3

Source DB: PubMed Journal: Endocrine ISSN： 1355-008X Impact factor: 3.633

× No keyword cloud information.

13 in total

1. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.

Authors: Kristin Mondy; William G Powderly; Sherry A Claxton; Kevin H Yarasheski; Michael Royal; John S Stoneman; Mary E Hoffmann; Pablo Tebas
Journal: J Acquir Immune Defic Syndr Date: 2005-04-01 Impact factor: 3.731

2. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort.

Authors: Fabio Vescini; Alessandro Cozzi-Lepri; Marco Borderi; Maria Carla Re; Franco Maggiolo; Andrea De Luca; Giovanni Cassola; Vincenzo Vullo; Giampiero Carosi; Andrea Antinori; Valerio Tozzi; Antonella Darminio Monforte
Journal: J Acquir Immune Defic Syndr Date: 2011-10-01 Impact factor: 3.731

3. High prevalence of radiological vertebral fractures in HIV-infected males.

Authors: Carlo Torti; Gherardo Mazziotti; Pier Antonio Soldini; Emanuele Focà; Roberto Maroldi; Daria Gotti; Giampiero Carosi; Andrea Giustina
Journal: Endocrine Date: 2011-12-25 Impact factor: 3.633

4. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

Authors: Mark J Bolland; Andrew Grey; Anne M Horne; Simon E Briggs; Mark G Thomas; Rod B Ellis-Pegler; Greg D Gamble; Ian R Reid
Journal: J Clin Endocrinol Metab Date: 2012-03-14 Impact factor: 5.958

5. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.

Authors: G Guaraldi; G Orlando; G Madeddu; F Vescini; P Ventura; S Campostrini; M S Mura; N Parise; R Caudarella; R Esposito
Journal: HIV Clin Trials Date: 2004 Sep-Oct

6. Bone-density testing interval and transition to osteoporosis in older women.

Authors: Margaret L Gourlay; Jason P Fine; John S Preisser; Ryan C May; Chenxi Li; Li-Yung Lui; David F Ransohoff; Jane A Cauley; Kristine E Ensrud
Journal: N Engl J Med Date: 2012-01-19 Impact factor: 91.245

7. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

Authors: Grace A McComsey; Michelle A Kendall; Pablo Tebas; Susan Swindells; Evelyn Hogg; Beverly Alston-Smith; Carol Suckow; Geetha Gopalakrishnan; Constance Benson; David A Wohl
Journal: AIDS Date: 2007-11-30 Impact factor: 4.177

Bisphosphonates in the treatment of HIV-related osteoporosis.

1. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.

2. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort.

3. High prevalence of radiological vertebral fractures in HIV-infected males.

4. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

5. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.

6. Bone-density testing interval and transition to osteoporosis in older women.

7. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

8. Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.

9. Prevalence of sub-clinical vertebral fractures in HIV-infected patients.

10. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

1. Exploring the role of the α-carboxyphosphonate moiety in the HIV-RT activity of α-carboxy nucleoside phosphonates.

2. Mycobacterium avium-intracellulare and the unpredictable course of hypercalcemia in an AIDS patient.